Literature DB >> 12018951

A high-throughput screening microplate test for the interaction of drugs with P-glycoprotein.

Alexia Garrigues1, Jérôme Nugier, Stéphane Orlowski, Eric Ezan.   

Abstract

P-glycoprotein (P-gp) is a multidrug transporter responsible for resistance to anticancer chemotherapy and physiologically involved in absorption, distribution, and excretion of a large number of hydrophobic xenobiotics. P-gp exhibits both an ATPase activity correlated with its drug transport function and a basal ATPase activity in the absence of any drug. We have developed a high-throughput screening test to detect specific interactions between drugs and P-gp. We took into account the existence of multiple binding sites on P-gp to propose and validate an optimized strategy, based on the modulation of the basal ATPase activity of P-gp and of the ATPase activity stimulated by three reference substrates (verapamil, vinblastine, and progesterone). The ATPase activity measurements were performed on P-gp-containing membrane vesicles from actinomycin-D-selected hamster DC-3F lung fibroblasts by a spectrophotometric method based on continuous monitoring of ADP formation, regenerated in ATP by a coupled enzyme system. This assay may be performed on 96- or 384-well microtiter plates. When applying this ATPase assay to 41 compounds known from the literature for their interaction with P-gp, 95% of them were found to be positive, whereas only 78% were positive when considering solely the modulation of the basal activity. (c) 2002 Elsevier Science (USA).

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12018951     DOI: 10.1006/abio.2002.5650

Source DB:  PubMed          Journal:  Anal Biochem        ISSN: 0003-2697            Impact factor:   3.365


  20 in total

1.  Establishment of ELISA on 384-well microplate for AFP, CEA, CA 19-9, CA 15-3, CA 125, and PSA-ACT: higher sensitivity and lower reagent cost.

Authors:  Tsu-Lan Wu; Yu-Chen Sun; Pi-Yueh Chang; Kuo-Chien Tsao; Chien-Feng Sun; James T Wu
Journal:  J Clin Lab Anal       Date:  2003       Impact factor: 2.352

2.  Future Perspectives for Brain Pharmacotherapies: Implications of Drug Transport Processes at the Blood-brain Barrier.

Authors:  Dirk M Hermann
Journal:  Ther Adv Neurol Disord       Date:  2008-11       Impact factor: 6.570

3.  Vitamin E reverses multidrug resistance in vitro and in vivo.

Authors:  Jingling Tang; Qiang Fu; Yongjun Wang; Kelly Racette; Dun Wang; Feng Liu
Journal:  Cancer Lett       Date:  2013-04-23       Impact factor: 8.679

4.  Isolated rafts from adriamycin-resistant P388 cells contain functional ATPases and provide an easy test system for P-glycoprotein-related activities.

Authors:  Karsten Bucher; Camille A Besse; Sarah W Kamau; Heidi Wunderli-Allenspach; Stefanie D Krämer
Journal:  Pharm Res       Date:  2005-03       Impact factor: 4.200

5.  Cell-free microfluidic determination of P-glycoprotein interactions with substrates and inhibitors.

Authors:  Klaus Eyer; Michael Herger; Stefanie D Krämer; Petra S Dittrich
Journal:  Pharm Res       Date:  2014-06-14       Impact factor: 4.200

Review 6.  Advancement of structure-activity relationship of multidrug resistance-associated protein 2 interactions.

Authors:  Li Xing; Yiding Hu; Yurong Lai
Journal:  AAPS J       Date:  2009-06-03       Impact factor: 4.009

7.  Nordihydroguaiaretic acid increases glutamate uptake in vitro and in vivo: therapeutic implications for amyotrophic lateral sclerosis.

Authors:  William Boston-Howes; Eric O Williams; Alexey Bogush; Maura Scolere; Piera Pasinelli; Davide Trotti
Journal:  Exp Neurol       Date:  2008-06-24       Impact factor: 5.330

8.  Predicting P-glycoprotein effects on oral absorption: correlation of transport in Caco-2 with drug pharmacokinetics in wild-type and mdr1a(-/-) mice in vivo.

Authors:  Andrew Collett; Jolanta Tanianis-Hughes; David Hallifax; Geoff Warhurst
Journal:  Pharm Res       Date:  2004-05       Impact factor: 4.200

9.  NVP-TAE684 reverses multidrug resistance (MDR) in human osteosarcoma by inhibiting P-glycoprotein (PGP1) function.

Authors:  Shunan Ye; Jianming Zhang; Jacson Shen; Yan Gao; Ying Li; Edwin Choy; Gregory Cote; David Harmon; Henry Mankin; Nathanael S Gray; Francis J Hornicek; Zhenfeng Duan
Journal:  Br J Pharmacol       Date:  2016-01-15       Impact factor: 8.739

10.  NSC23925, identified in a high-throughput cell-based screen, reverses multidrug resistance.

Authors:  Zhenfeng Duan; Edwin Choy; Francis J Hornicek
Journal:  PLoS One       Date:  2009-10-12       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.